Ulasov IV - Search Results

1

Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.

Zhu ZB, Makhija SK, Lu B, Wang M, Rivera AA, Kim-Park S, Ulasov IV, Zhou F, Alvarez RD, Siegal GP, Curiel DT. Zhu ZB, et al. Among authors: ulasov iv. Int J Oncol. 2005 Jul;27(1):237-46. Int J Oncol. 2005. PMID: 15942665

2

Characterization of infectivity of knob-modified adenoviral vectors in glioma.

Paul CP, Everts M, Glasgow JN, Dent P, Fisher PB, Ulasov IV, Lesniak MS, Stoff-Khalili MA, Roth JC, Preuss MA, Dirven CM, Lamfers ML, Siegal GP, Zhu ZB, Curiel DT. Paul CP, et al. Among authors: ulasov iv. Cancer Biol Ther. 2008 May;7(5):786-93. doi: 10.4161/cbt.7.5.5421. Cancer Biol Ther. 2008. PMID: 18756624 Free article.

3

The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.

Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, Dirven CM, Curiel DT, Zhu ZB. Van Houdt WJ, et al. Among authors: ulasov iv. J Neurosurg. 2006 Apr;104(4):583-92. doi: 10.3171/jns.2006.104.4.583. J Neurosurg. 2006. PMID: 16619663

4

Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.

Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS. Ulasov IV, et al. Hum Gene Ther. 2007 Jul;18(7):589-602. doi: 10.1089/hum.2007.002. Hum Gene Ther. 2007. PMID: 17630837

5

An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.

Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT, Lesniak MS. Ulasov IV, et al. Int J Oncol. 2007 Nov;31(5):1177-85. Int J Oncol. 2007. PMID: 17912445

6

Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy.

Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC, Lesniak MS. Ulasov IV, et al. Int J Oncol. 2009 Mar;34(3):729-42. doi: 10.3892/ijo_00000199. Int J Oncol. 2009. PMID: 19212678 Free PMC article.

7

Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy.

Breidenbach M, Rein DT, Wang M, Nettelbeck DM, Hemminki A, Ulasov I, Rivera AR, Everts M, Alvarez RD, Douglas JT, Curiel DT. Breidenbach M, et al. Hum Gene Ther. 2004 May;15(5):509-18. doi: 10.1089/10430340460745829. Hum Gene Ther. 2004. PMID: 15144580

8

A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.

Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT. Kirby TO, et al. Clin Cancer Res. 2004 Dec 15;10(24):8697-703. doi: 10.1158/1078-0432.CCR-04-1166. Clin Cancer Res. 2004. PMID: 15623655

9

Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.

Ulasov IV, Rivera AA, Sonabend AM, Rivera LB, Wang M, Zhu ZB, Lesniak MS. Ulasov IV, et al. Cancer Biol Ther. 2007 May;6(5):679-85. doi: 10.4161/cbt.6.5.3957. Epub 2007 Feb 3. Cancer Biol Ther. 2007. PMID: 17404502 Free article.

10

Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells.

Ulasov IV, Rivera AA, Han Y, Curiel DT, Zhu ZB, Lesniak MS. Ulasov IV, et al. J Neurosurg. 2007 Sep;107(3):617-27. doi: 10.3171/JNS-07/09/0617. J Neurosurg. 2007. PMID: 17886563

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters